Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
December 09 2021 - 4:01PM
Business Wire
Conference Call to be held Thursday, December
16, 2021 at 5:00 pm (EST)
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced a conference call to provide updates and discuss
strategy, as well as the resignation of Thomas Farb and Agnieszka
Winkler as members of the Company’s Board of Directors (the
“Board”), effective December 5, 2021.
The Company will hold the conference call and webcast on
Thursday, December 16, 2021 at 5:00 p.m. (EST). Chairman Alexander
L. Cappello, Vice Chairman John K. Scott, Jr., and Chief Medical
Officer Dr. Michael Rosol will host the call and webcast to provide
an update on recent developments and clinical progress.
Michael Rosol, Navidea’s Chief Medical Officer, said, “The
senior management of the Company, as well as the Board of
Directors, are eager to hold this informational Q&A call with
our shareholders to provide updates and outline strategy as we move
forward.”
Alexander L. Cappello, Chair of Navidea’s Board of Directors,
said, “We look forward to the discussion on the 16th and getting to
know our investors and addressing their interests and concerns. We
also wish to thank both Thomas Farb and Agnieszka Winkler for their
outstanding service on the Board and the valuable insights they
have provided during this time of transition for the Company. Their
contributions helped shape the direction of the Company as we move
forward. We wish them the best in their future endeavors.”
To participate in the call and webcast, please refer to the
information below:
Event: Navidea Biopharmaceuticals Business
Update
Date: Thursday, December 16, 2021
Time: 5:00 p.m. (EST)
U.S. & Canada Dial-In: 877-407-0312
International Dial-In: +1 201-389-0899
Conference ID: 13725627
Webcast Link:
https://webcast-eqs.com/navidbioph20211216/en
A live audio webcast of the conference call will also be
available on the investor relations page of Navidea’s corporate
website at www.navidea.com. In addition, the recorded conference
call can be replayed and will be available for 90 days following
the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211209005986/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. Jeffrey Smith Vice President of Operations 614-822-2365
jsmith@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024